“Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)”, J of Skin, vol. 5, no. 1, p. s4, Jan. 2021, doi: 10.25251/skin.5.supp.4.